1. Home
  2. PBT vs JANX Comparison

PBT vs JANX Comparison

Compare PBT & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permian Basin Royalty Trust

PBT

Permian Basin Royalty Trust

N/A

Current Price

$31.51

Market Cap

1.0B

Sector

Energy

ML Signal

N/A

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

N/A

Current Price

$17.54

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PBT
JANX
Founded
1980
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PBT
JANX
Price
$31.51
$17.54
Analyst Decision
Strong Buy
Analyst Count
0
18
Target Price
N/A
★ $33.81
AVG Volume (30 Days)
78.3K
★ 751.0K
Earning Date
11-11-2026
11-09-2026
Dividend Yield
★ 0.87%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $10,000,000.00
Revenue This Year
N/A
$194.24
Revenue Next Year
N/A
N/A
P/E Ratio
$57.37
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$16.25
$12.12
52 Week High
$37.00
$35.34

Technical Indicators

Market Signals
Indicator
PBT
JANX
Relative Strength Index (RSI) 36.82 51.36
Support Level $30.72 $15.90
Resistance Level $32.25 $19.16
Average True Range (ATR) 1.15 0.83
MACD -0.22 0.07
Stochastic Oscillator 6.26 48.72

Price Performance

Historical Comparison
PBT
JANX

About PBT Permian Basin Royalty Trust

Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole, and others across Texas. The company earns the majority of its revenue in the form of royalties received through its properties.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: